FibroBiologics, Inc. (NASDAQ:FBLG – Get Free Report) saw a large increase in short interest during the month of August. As of August 31st, there was short interest totalling 1,500,000 shares, an increase of 33.9% from the August 15th total of 1,120,000 shares. Currently, 5.6% of the company’s shares are short sold. Based on an average trading volume of 418,700 shares, the days-to-cover ratio is currently 3.6 days.
Analyst Ratings Changes
Separately, EF Hutton Acquisition Co. I upgraded shares of FibroBiologics to a “strong-buy” rating in a research report on Wednesday, September 4th.
Get Our Latest Stock Report on FibroBiologics
FibroBiologics Stock Performance
FibroBiologics (NASDAQ:FBLG – Get Free Report) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.09) EPS for the quarter, meeting the consensus estimate of ($0.09). On average, analysts forecast that FibroBiologics will post -0.37 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of FBLG. Fund Evaluation Group LLC acquired a new position in shares of FibroBiologics during the 2nd quarter worth approximately $5,265,000. Cascade Financial Partners LLC bought a new stake in FibroBiologics in the 2nd quarter valued at $1,572,000. Transform Wealth LLC bought a new stake in FibroBiologics in the 2nd quarter valued at $668,000. Bank of New York Mellon Corp acquired a new position in FibroBiologics in the 2nd quarter valued at $342,000. Finally, RMR Wealth Builders bought a new position in FibroBiologics during the 2nd quarter worth $186,000.
About FibroBiologics
FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.
Featured Articles
- Five stocks we like better than FibroBiologics
- How to Invest in Insurance Companies: A GuideĀ
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- Best Aerospace Stocks Investing
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- How to invest in marijuana stocks in 7 stepsĀ
- 5 Oversold Stocks to Buy Right Now
Receive News & Ratings for FibroBiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroBiologics and related companies with MarketBeat.com's FREE daily email newsletter.